Mostrar el registro sencillo del ítem

dc.contributor.author
Talevi, Alan  
dc.date.available
2020-01-14T18:58:18Z  
dc.date.issued
2018-01  
dc.identifier.citation
Talevi, Alan; Drug repositioning: current approaches and their implications in the precision medicine era; Taylor & Francis; Expert Review of Precision Medicine and Drug Development; 3; 1; 1-2018; 49-61  
dc.identifier.issn
2380-8993  
dc.identifier.uri
http://hdl.handle.net/11336/94633  
dc.description.abstract
Introduction: Drug repositioning implies finding new medical uses for existing drugs. It represents a cost-efficient approach, since the new indications are built on the basis of available information on pharmacokinetics, safety and manufacturing. Whereas most of the pioneering drug repurposing stories arose from serendipitous observations and clever exploitation of side effects, the drug discovery community has lately addressed repurposing initiatives in a more systematic manner. Today, in the middle of the omics era, we have the tools to explore drug repurposing opportunities in a tailored, personalized manner. Areas covered: After a brief discussion on modern approaches to drug repurposing, the author connects the philosophies of drug repurposing and personalized medicine through the well-known and extended practice of off-label prescription. The author also discusses which, among current systematic repurposing approaches, are more appropriate to be integrated with the field of precision medicine. Expert commentary: Personalized drug repurposing is not a new concept at all: for years, it has been known as off-label prescription, a practice widely accepted especially in some branches of medicine. Whereas in the past such approach was in many cases supported by empiric knowledge, today omics technologies allow us to face novel personalized drug repurposing options in a systematic manner.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Taylor & Francis  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
DRUG REPURPOSING  
dc.subject
DRUG REPOSITIONING  
dc.subject
PERSONALIZED MEDICINE  
dc.subject
PRECISION MEDICINE  
dc.subject
GENOME-WIDE ASSOCIATION STUDIES  
dc.subject
GWAS  
dc.subject
OMICS  
dc.subject
OFF-LABEL PRESCRIPTION  
dc.subject
THERAPEUTIC INDICATION EXPANSION  
dc.subject
THERAPEUTIC INDICATION SHIFT  
dc.subject.classification
Otros tipos de Medicina Clínica  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Drug repositioning: current approaches and their implications in the precision medicine era  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2019-10-23T21:40:55Z  
dc.journal.volume
3  
dc.journal.number
1  
dc.journal.pagination
49-61  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Departamento de Ciencias Biológicas. Cátedra de Química Medicinal; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.journal.title
Expert Review of Precision Medicine and Drug Development  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/23808993.2018.1424535  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1080/23808993.2018.1424535